LGND Live signals | Maximize Profits with Getagraph.com

SELL 102293 min ago

@ $73.34

Issued: 14 Feb 2024 @ 10:26

Return: -3.53%

Previous signal: Feb 13 - 09:30

Previous signal: Buy

Return: -1.89 %

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 12:10):

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide...

Stats
Today's Volume	33 673.00
Average Volume	174 309
Market Cap	1.25B
EPS	$0 ( 2024-02-27 )
Next earnings date	( $1.130 ) 2024-05-02
Last Dividend	$0.456 ( 2010-07-02 )
Next Dividend	$0 ( N/A )
P/E	23.35
ATR14	$0.161 (0.23%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-25	Davis Todd C	Buy	3 556	Common Stock
2024-03-25	Davis Todd C	Buy	2 156	Common Stock
2024-03-25	Davis Todd C	Buy	2 855	Common Stock
2024-03-25	Davis Todd C	Buy	7 448	Common Stock
2024-03-25	Davis Todd C	Sell	2 156	Non-Qualified Stock Option (right to buy)

INSIDER POWER
78.13
Last 99 transactions
Buy: 889 086 \| Sell: 99 886

Volume Correlation

Long: 0.24 (neutral)

Short: -0.01 (neutral)

Signal:(58.719) Neutral

Ligand Pharmaceuticals Correlation

10 Most Positive Correlations
ALSK	0.829
NVEC	0.811

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Ligand Pharmaceuticals Correlation - Currency/Commodity

-0.22
( neutral )

-0.01
( neutral )

0.00
( neutral )

-0.43
( neutral )

0.62
( weak )

0.38
( neutral )

Ligand Pharmaceuticals Financials

Annual	2023
Revenue:	$131.31M
Gross Profit:	$119.75M (91.20 %)
EPS:	$3.02

Q4	2023
Revenue:	$28.10M
Gross Profit:	$26.44M (94.08 %)
EPS:	$1.040

Q3	2023
Revenue:	$32.87M
Gross Profit:	$29.38M (89.40 %)
EPS:	$-0.740

Q2	2023
Revenue:	$26.37M
Gross Profit:	$24.70M (93.67 %)
EPS:	$0.130

Financial Reports:

No articles found.

Ligand Pharmaceuticals Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Ligand Pharmaceuticals Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 8.02 - good (80.23%) | Divividend Growth Potential Score: 1.513 - No dividend growth expected in the near future

Information

First Dividend	$9.36	2007-04-03
Last Dividend	$0.456	2010-07-02
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	2	--
Total Paid Out	$9.81	--
Avg. Dividend % Per Year	0.00%	--
Score	1.65	--
Div. Sustainability Score	8.02
Div.Growth Potential Score	1.513
Div. Directional Score	4.77	--

Next Divdend (Est)
(2026-09-30)

$0 Estimate 0.00 %

Dividend Stability

0.01 Very Bad

Dividend Score

1.65

Pay Frequency

Sporadic

Yearly Payout

Year	Amount	Yield
2007	$9.36	14.30%
2008	$0	0.00%
2009	$0	0.00%
2010	$0.456	3.50%
2011	$0	0.00%
2012	$0	0.00%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.378	1.500	2.44	3.66	[0 - 0.5]
returnOnAssetsTTM	0.0596	1.200	8.01	9.62	[0 - 0.3]
returnOnEquityTTM	0.0742	1.500	-0.287	-0.431	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	14.15	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	12.49	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	1.368	1.500	3.51	5.27	[0.2 - 2]
debtRatioTTM	0.00740	-1.500	9.88	-10.00	[0 - 0.6]
interestCoverageTTM	2.60	1.000	-0.148	-0.148	[3 - 30]
operatingCashFlowPerShareTTM	2.84	2.00	9.05	10.00	[0 - 30]
freeCashFlowPerShareTTM	-0.245	2.00	-0.122	-0.245	[0 - 20]
debtEquityRatioTTM	0.00880	-1.500	9.96	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.920	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.0666	1.000	-0.669	-0.669	[0.1 - 0.6]
cashFlowToDebtRatioTTM	8.04	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.158	0.800	-2.28	-1.826	[0.5 - 2]
Total Score				8.02

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	24.98	1.000	7.58	0	[1 - 100]
returnOnEquityTTM	0.0742	2.50	-0.185	-0.431	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.245	2.00	-0.0815	-0.245	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	2.84	2.00	9.05	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.0119	1.500	-3.25	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.378	1.000	3.06	0	[0.1 - 0.5]
Total Score				1.513

Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.